A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 34,372 shares of BMY stock, worth $1.99 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
34,372
Previous 34,964 1.69%
Holding current value
$1.99 Million
Previous $1.45 Million 22.45%
% of portfolio
0.07%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $23,478 - $30,636
-592 Reduced 1.69%
34,372 $1.78 Million
Q2 2024

Aug 12, 2024

SELL
$40.25 - $52.99 $37,392 - $49,227
-929 Reduced 2.59%
34,964 $1.45 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $1.38 Million - $1.56 Million
-28,746 Reduced 44.47%
35,893 $1.95 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $67,872 - $80,990
1,400 Added 2.21%
64,639 $3.32 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $1.77 Million - $1.97 Million
30,510 Added 93.22%
63,239 $3.67 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $117,927 - $130,939
1,851 Added 5.99%
32,729 $2.09 Million
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $2.02 Million - $2.29 Million
-30,706 Reduced 49.86%
30,878 $2.14 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $2.53 Million - $2.99 Million
-36,875 Reduced 37.45%
61,584 $4.43 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $1,023 - $604,730
-7,870 Reduced 7.4%
98,459 $7 Million
Q2 2022

Aug 16, 2022

BUY
$72.62 - $79.98 $1.83 Million - $2.01 Million
25,150 Added 30.98%
106,329 $8.19 Million
Q1 2022

May 17, 2022

SELL
$61.48 - $73.72 $255,264 - $306,085
-4,152 Reduced 4.87%
81,179 $5.93 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $6,167 - $7,189
-115 Reduced 0.13%
85,331 $5.32 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $128,339 - $150,333
-2,169 Reduced 2.48%
85,446 $5.06 Million
Q2 2021

Aug 13, 2021

SELL
$61.91 - $67.42 $27,240 - $29,664
-440 Reduced 0.5%
87,615 $5.85 Million
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $2.45 Million - $2.76 Million
41,358 Added 88.57%
88,055 $5.56 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $464,807 - $526,711
8,050 Added 20.83%
46,697 $2.9 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $1.04 Million - $1.16 Million
-18,170 Reduced 31.98%
38,647 $2.33 Million
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $1.49 Million - $1.74 Million
27,090 Added 91.13%
56,817 $3.34 Million
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $1.82 Million - $2.65 Million
-39,280 Reduced 56.92%
29,727 $1.66 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $617,880 - $805,969
12,556 Added 22.24%
69,007 $4.43 Million
Q3 2019

Nov 13, 2019

SELL
$42.77 - $50.71 $95,377 - $113,083
-2,230 Reduced 3.8%
56,451 $2.86 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $119,224 - $131,836
2,672 Added 4.77%
58,681 $2.66 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $15,250 - $18,184
338 Added 0.61%
56,009 $2.67 Million
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $318,744 - $413,334
6,537 Added 13.3%
55,671 $2.89 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $44,152 - $49,800
-800 Reduced 1.6%
49,134 $3.05 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $71,752 - $89,431
-1,420 Reduced 2.77%
49,934 $2.76 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $107,256 - $123,474
-1,790 Reduced 3.37%
51,354 $3.25 Million
Q4 2017

Feb 13, 2018

BUY
$59.94 - $65.35 $258,940 - $282,312
4,320 Added 8.85%
53,144 $3.26 Million
Q3 2017

Nov 08, 2017

BUY
$55.23 - $63.74 $2.7 Million - $3.11 Million
48,824
48,824 $3.11 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Meiji Yasuda Asset Management CO Ltd. Portfolio

Follow Meiji Yasuda Asset Management CO Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Asset Management CO Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Asset Management CO Ltd. with notifications on news.